JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

ALNY - Alnylam Pharmaceuticals, Inc.

USD|NASDAQ|Healthcare

ALNY Financials - Alnylam Pharmaceuticals Income & Cash Flow | Ledgeburg

Financials of ALNY

Revenue$3.713937B

Operating Income$501.578M

Net Income$313.747M

Share Count (Basic)131.004M

Operating Cash Flow$524.08M

Free Cash Flow$465.383M

Cash And Short-Term Equivalents$1.65725B

Total DebtN/A

AnnualQuarterly

Revenue $USD

01B2B3B4B

FY2021FY2022FY2023FY2024FY2025

AnnualQuarterly

Net Income $USD

-1B-500M0

FY2021

AnnualQuarterly

Margins

GrossOperatingNet

-100%-50%0%50%100%